Dopamine D2 receptor-mediated G-protein activation in rat striatum: Functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra

Brain Research

Volumn 920, Issue 1-2, 2001, Pages 41-54

  Newman Tancredi, Adrian ^a   Cussac, Didier ^a   Brocco, Mauricette ^a   Rivet, Jean Michel ^a   Chaput, Christine ^a   Touzard, Manuelle ^a   Pasteau, Valérie ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

35S GTP S; Quinelorane; S18126; S33084

Indexed keywords

1 (1,4 BENZODIOXAN 6 YL) 4 (2 INDANYLMETHYL)PIPERAZINE; 4 (4 CHLOROPHENYL) 1 (1H INDOL 3 YLMETHYL)PIPERIDIN 4 OL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H BENZOPYRANO[3,4 C]PYRROL 2 YL)BUTYL] 4 PHENYLBENZAMIDE; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H-BENZOPYRANO[3,4 C]PYRROLE 2 YL)BUTYL] 4 PHENYLBENZAMIDE; OXIDOPAMINE; QUINELORANE; RACLOPRIDE; RECEPTOR SUBTYPE; SULFUR 35; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, HUMAN; DRD3 PROTEIN, RAT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BRAIN INJURY; CINGULATE GYRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; HUMAN; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; RAT; SUBSTANTIA NIGRA; ANIMAL; BINDING COMPETITION; BIOTRANSFORMATION; BRAIN LEVEL; CHEMICAL SYMPATHECTOMY; METABOLISM; NEOSTRIATUM; PHYSIOLOGY; STEREOTYPY;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BIOTRANSFORMATION; BRAIN CHEMISTRY; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; NEOSTRIATUM; OXIDOPAMINE; QUINOLINES; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECOMBINANT PROTEINS; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; SYMPATHECTOMY, CHEMICAL; SYMPATHOLYTICS;

EID: 0035976266     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02927-4     Document Type: Article

References (59)

1. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat
2. 2 receptors
3. Dopamine agonists in schizophrenia: A review
4. Experimental models of Parkinson's disease: From the static to the dynamic
5. 2 dopamine receptors in 6-OHDA-lesioned rats receiving fœtal ventral mesencephalic grafts and chronic treatment with L-DOPA and carbidopa
6. 3 receptor expression as a mechanism of behavioural sensitisation to levodopa
7. 2 receptor antagonist L-741,626
8. 2 dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats
9. Dopamine receptor coupling to adenylyl cyclase in rat olfactory pathway: A combined pharmacological-radioautographic approach
10. 3 receptors mediate MAPK activation via a PI3-kinase and an atypical PKC-dependent mechanism
11. Dopamine agonist-induced elevation of striatal acetylcholine: Relationship between receptor occupancy and response in normal and denervated striatum
12. Super-sensitivity time course of dopamine antagonist binding after nigrostriatal denervation: Evidence for early and drastic changes in the rat corpus striatum
13. 2-dopaminergic agonist
14. 3 dopamine receptors in the rat brain
15. 35S]GTPγS binding
16. 35S]GTPγS binding in striatum of 6-hydroxydopamine-lesioned rats
17. Parkinson's disease: Prospects for improved drug therapy
18. 2-Adrenoceptor-stimulated GTPγS binding in rat brain: An autoradiographic study
19. 35S]GTPγS binding in rat striatum
20. The rationale for the use of dopamine agonists in Parkinson's disease
21. 2 receptor
22. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G-protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions
23. Dopamine receptor supersensitivity
24. 35S]guanosine-5′-(γ-thio)triphosphate autoradiography
25. 3 dopamine receptor: Neurobiology and potential clinical relevance
26. 3 receptor functions?
27. Anatomy of the dopaminergic neuron systems in the rat brain
28. Striatal G-proteins: Effects of unilateral 6-hydroxydopamine lesions
29. 1A agonist LY165,163 induces contralateral rotation in unilateral substantia nigra-lesioned rats via dopamine receptors
30. 4 receptors: An in vitro and in vivo comparison with L745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride
31. 3 receptors: 1. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
32. Dopamine receptors: From structure to function
33. 35S]GTPγS binding in brain: Modulation by endogenous adenosine
34. 1A receptors as a function of receptor: G-protein stoichiometry
35. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents
36. 35S]GTPγS binding and antibody study
37. 3H]S15535 autoradiography study
38. 35S]GTPγS autoradiography study
39. 2 adrenoceptor-mediated G-protein activation in amygdala and lateral septum
40. 1B receptor/G-protein stoichiometry
41. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
42. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: Effect of levodopa treatment
43. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
44. Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: Implications for human Parkinson's disease
45. 35S]GTPγS) binding in rat striatal membranes
46. Autoradiography of receptor-activated G-proteins in post mortem human brain
47. 2 receptor is elevated in the striatum of Parkinson's disease
48. 2 receptors
49. 35S]thio]triphosphate binding
50. Differences in G-protein activation by μ- and δ-opioid and cannabinoid receptors in rat striatum
51. 2 receptor
52. Dopamine receptor changes following destruction of the nigrostriatal pathway: Lack of a relationship to rotational behaviour
53. Sodium-dependent interaction of benzamides with dopamine receptors
54. Comparative review of dopamine receptor agonists in Parkinson's disease
55. Post-synaptic supersensitivity after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine system
56. 3 receptors in Chinese hamster ovary cells
57. 35S]guanosine-5′-O-(3-thio)triphosphate binding to rodent brain sections as visualised by in vitro autoradiography
58. 2 dopamine receptors